Navigation Links
More patients with drug-coated cardiac stents survive, avoid costly follow-up procedures
Date:5/22/2008

(PHILADELPHIA) The more than ten million Americans whove received drug-eluting stents to open their blocked coronary arteries have a bright future, according to new research from the University of Pennsylvania School of Medicine.

The findings, among the first large follow-up studies to show a clear, lifesaving benefit of drug-eluting stents compared to bare metal stents, will be published in the May 27 issue of the Journal of the American College of Cardiology. Patients with the drug-coated stents -- designed not only to open blocked coronary arteries but also to chemically inhibit future blockage -- were less apt to die, have heart attacks or require extra stents or bypass surgery in the two years following placement of the stent.

This might be a hidden nugget of goodness that could not be detected in clinical trials, says Peter W. Groeneveld, MD, MS, assistant professor in Penns Division of General Internal Medicine. There is a distinct possibility that drug-eluting stents not only reduce the need for future cardiac procedures, but also save lives.

Groeneveld and his colleagues studied Medicare data to identify about 72,000 patients who received drug-eluting stents during a nine-month period in 2003, the first year the devices were approved for use in the United States. Overall, the findings showed a clear survival benefit compared to a control group of patients who got bare metal stents -- at 90 days, 1 year and 2 years, patients with drug-coated stents were less likely to die.

In a separate study which will be published in the June issue of the American Heart Journal, Groeneveld also found that drug-eluting stents also offer cost savings during the first year after placement. Although the initial cost of the device averaging $16,000 -- outpaces that of a bare metal stent, which costs about $14,000, the Penn researchers found that among patients with the drug-coated stents, 12 percent of those studied needed additional
'/>"/>

Contact: Holly Auer
holly.auer@uphs.upenn.edu
215-200-2313
University of Pennsylvania School of Medicine
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Fluctuating eye pressure associated with visual field deterioration in glaucoma patients
2. Comparison of obstetric outcomes between on-call and patients own obstetricians
3. Vision restoration therapy shown to improve brain activity in brain injured patients
4. Diabetes appears to increase risk of death for patients with acute coronary syndromes
5. Ambulatory oxygen rarely a benefit in COPD patients without resting hypoxemia
6. Restricting Blood Flow May Help Heart Bypass Patients
7. Patients with Medicaid and those lacking insurance have higher risk of advanced laryngeal cancer
8. Study provides hope that some transplant patients could live free of antirejection drugs
9. Study provides hope that some transplant patients could live free of anti-rejection drugs
10. Longer ambulance journeys boost death risk for seriously ill patients
11. Expenses Overshadow Optimism for Kidney Failure Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... 2015 New Jersey Governor First ... First Spouses from across the country in sponsoring ... 2015, World Down Syndrome Day(WDSD), to increase awareness ... area of Down syndrome cognition research. , In ... Alaska, American Samoa, Arizona, California, Colorado, Delaware, Florida, ...
(Date:4/1/2015)... Taking an important step forward in ... Nursing Commission for Nursing Education Accreditation (NLN CNEA) , ... NLN CNEA Board of Commissioners. Working with executive director ... board will provide leadership and direction to accreditation services ... for nursing programs that seek accreditation from the CNEA. ...
(Date:4/1/2015)... (PRWEB) April 01, 2015 It all began ... Patricia Di Gasbarro, who was on a mission to create ... and simple ingredients that parents could trust. Now, Shoosha Truly ... Grade Organic skincare products, meaning all products contain a minimum ... America. , Babies’ skin is considered to be 40% thinner ...
(Date:4/1/2015)... MD, Alexandria, VA (PRWEB) April 01, 2015 ... (ASCP), the College of American Pathologists (CAP), the ... Society of Clinical Oncology (ASCO) today released a ... use of molecular marker testing for patients with ... will help establish standard molecular marker testing, guide ...
(Date:4/1/2015)... SCI Solutions , the health industry’s ... that CEO Joel French will be a featured speaker ... in Chicago, April 12-16, 2015. French will co-present ... Coordination Strategies ” with Northeast Georgia Health System (NGHS) ... than 38,000 healthcare industry professionals are expected at the ...
Breaking Medicine News(10 mins):Health News:Governor First Spouses Join with New Jersey First Lady Mary Pat Christie to Support Advances in Biomedical Research to Treat Down Syndrome Cognitive Impairment 2Health News:NLN Commission for Nursing Education Accreditation (NLN CNEA) Announces Inaugural Commissioners 2Health News:NLN Commission for Nursing Education Accreditation (NLN CNEA) Announces Inaugural Commissioners 3Health News:Just in Time for Earth Day This April, Shoosha Truly Organic’s Skincare Line Soothes and Protects Mom and Baby’s Sensitive Skin with Pure, Simple and Organic Ingredients 2Health News:Just in Time for Earth Day This April, Shoosha Truly Organic’s Skincare Line Soothes and Protects Mom and Baby’s Sensitive Skin with Pure, Simple and Organic Ingredients 3Health News:ASCP, CAP, AMP, and ASCO Issue Draft Colorectal Cancer Molecular Marker Testing Guideline and Announce Opening of Public Comment Period 2Health News:ASCP, CAP, AMP, and ASCO Issue Draft Colorectal Cancer Molecular Marker Testing Guideline and Announce Opening of Public Comment Period 3Health News:ASCP, CAP, AMP, and ASCO Issue Draft Colorectal Cancer Molecular Marker Testing Guideline and Announce Opening of Public Comment Period 4Health News:SCI Solutions CEO Joel French and Northeast Georgia Health System to Present at HIMSS15 2Health News:SCI Solutions CEO Joel French and Northeast Georgia Health System to Present at HIMSS15 3Health News:SCI Solutions CEO Joel French and Northeast Georgia Health System to Present at HIMSS15 4
... Expands Cutting-Edge Patient Safety Technology, HONOLULU, ... today,that The Queen,s Medical Center will equip ... LifeBed(TM) Patient Vigilance Systems,(LifeBed), bringing the total ... Hoana,s technology transforms any bed into a ...
... Southern California Celebrity Gala, COSTA MESA, Calif., Aug. ... a major fundraiser to benefit,families affected by autism with ... McCarthy and Armstrong host the celebrity-packed evening Ante ... in Dana Point, California on,Friday, October 3, 2008. Joining ...
... Aug. 5 The National Parkinson,Foundation (NPF) announced ... to Parkinson,s disease research, care and outreach worldwide.,Grants ... of 44,centers of excellence, 10 comprehensive care centers, ... more than 50,000 patients with,Parkinson,s disease and almost ...
... Currently Used for Executive Communication, Training and Disaster ... ... Telanetix, Inc. (OTC,BB: TNXI), a leading IP solutions provider offering telepresence ... Service has been selected by St. Vincent Catholic Medical,Centers of New ...
... (NYSE: PG ) announced net sales growth of 10 ... nine percent net sales growth for the,fiscal year to $83.5 ... and the fiscal year. This marks the seventh year and ... above the,company,s targets., Diluted net earnings per share increased ...
... Toronto Stock Exchange Symbol: CYT, MONTREAL, Aug. 5 ... products to treat cardiac,arrhythmias, today announced financial results for ... Third Quarter Financial and Operational Highlights: - ... a 12.0% increase over comparable ...
Cached Medicine News:Health News:Hoana Medical Expands Partnership With The Queen's Medical Center to Improve Patient Safety 2Health News:Hoana Medical Expands Partnership With The Queen's Medical Center to Improve Patient Safety 3Health News:Jenny McCarthy and Lance Armstrong Top Celebrity List to Raise Funds for Autism 2Health News:National Parkinson Foundation Awards $3.7 Million in Grants 2Health News:St. Vincent's Catholic Medical Centers of New York Select Telanetix Telepresence Solution 2Health News:St. Vincent's Catholic Medical Centers of New York Select Telanetix Telepresence Solution 3Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 2Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 3Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 4Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 5Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 6Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 7Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 8Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 9Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 10Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 11Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 12Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 13Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 14Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 15Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 16Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 17Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 18Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 19Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 20Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 21Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 22Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 23Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 24Health News:CryoCath Announces Fiscal 2008 Third Quarter Results 2Health News:CryoCath Announces Fiscal 2008 Third Quarter Results 3Health News:CryoCath Announces Fiscal 2008 Third Quarter Results 4Health News:CryoCath Announces Fiscal 2008 Third Quarter Results 5Health News:CryoCath Announces Fiscal 2008 Third Quarter Results 6Health News:CryoCath Announces Fiscal 2008 Third Quarter Results 7
(Date:4/1/2015)... 1, 2015 Trinity Biotech plc (Nasdaq: ... of diagnostic products for the point-of-care and clinical ... Limited, its wholly-owned subsidiary (the "Issuer"), intends to ... million aggregate principal amount of Exchangeable Senior Notes ... institutional buyers pursuant to Rule 144A under the ...
(Date:4/1/2015)... 1, 2015  Pittman Motors has significantly expanded ... PLG42K, PLG42S, PLG52, and PLG63 planetary gearboxes. These ... brushless DC motors and complement Pittman,s existing spur ... 35 standard motor-gearbox family combinations to the Pittman ... high torque loads with excellent efficiency and are ...
(Date:4/1/2015)... MOUNTAIN VIEW, Calif. , April 1, ... ) announces that it has signed a definitive ... device company that develops, manufactures and sells minimally ... drainage of targeted areas within the gastrointestinal tract. ... The Xlumena portfolio includes the ...
Breaking Medicine Technology:Trinity Biotech plc Announces Proposed Offering of $100 Million of Exchangeable Senior Notes due 2045 2Trinity Biotech plc Announces Proposed Offering of $100 Million of Exchangeable Senior Notes due 2045 3Trinity Biotech plc Announces Proposed Offering of $100 Million of Exchangeable Senior Notes due 2045 4Pittman Motors Expands PLG Planetary Gearbox Offering 2Boston Scientific Agrees to Acquire Xlumena 2Boston Scientific Agrees to Acquire Xlumena 3Boston Scientific Agrees to Acquire Xlumena 4Boston Scientific Agrees to Acquire Xlumena 5
... Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: ... specializing in the development, manufacturing, and marketing of ... that Shanghai Celgen Bio-Pharmaceutical Co., Ltd. ("Shanghai Celgen") ... interest, has received new drug registration approval for ...
... Cempra Pharmaceuticals, a developer of differentiated antibiotics, ... (IV) solithromycin demonstrates excellent tolerability and ... up to 800 mg.  Oral administration of solithromycin ... 1 studies.  The presentation will be at the ...
Cached Medicine Technology:Simcere Announces Recent Progress of Qiangke's Registration 2Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 2Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 3Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 4Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 5Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 6Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 7
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: